Unaudited Standalone/ Consolidated Financial Results for the Quarter ended December 31, 2024.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 5.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gian Life Care reported a sharp year-on-year decline in both revenue and profit for the quarter ended December 31, 2024. Standalone revenue from operations fell to Rs. 158.86 lacs in Q3 FY25 from Rs. 379.06 lacs in Q3 FY24, a drop of about 58%. Nine-month revenue declined to Rs. 551.76 lacs from Rs. 851.68 lacs. Standalone profit after tax for Q3 came in at Rs. 38.37 lacs versus Rs. 162.64 lacs a year ago, while nine-month PAT fell to Rs. 63.18 lacs from Rs. 209.58 lacs. Consolidated figures were broadly similar, with Q3 PAT of Rs. 35.19 lacs and nine-month PAT of Rs. 56.12 lacs. Basic EPS for Q3 on a standalone basis was Rs. 0.37. The auditor, MSNT & Associates LLP, issued a clean limited review report with no qualifications or concerns.
Sharply lower revenue and profits year-on-year point to significant business slowdown, which is likely to weigh negatively on the stock and erode investor confidence despite the unqualified auditor opinion.